Sponsored Links
| First Oral Drug For Uveitis Reduces Both Inflammation And Recurrence Rate In Potentially Blinding Eye Disease, Reports Lux Biosciences |
 |
 |
 |
| Medical News - Eye Health | |||
|
Uveitis, or inflammation within the eye, is a group of diseases responsible for years of visual loss roughly comparable to that caused by diabetes. Now, results from a pioneering international Phase 3 program in uveitis, the LUMINATE trials sponsored by Lux Biosciences, demonstrate the ability of LX211 (LUVENIQ™, voclosporin oral capsule) to significantly improve this chronic eye inflammation. Read more: Eye Health / Blindness News From Medical News Today
|